These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 5625259)

  • 1. [Myasthenia gravis. I. The action of anti-cholinesterase drugs on normal human extraocular muscles].
    Sato Y
    Nippon Ganka Gakkai Zasshi; 1967 Jul; 71(7):989-99. PubMed ID: 5625259
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.
    Manoguerra A; Whitney C; Clark RF; Anderson B; Turchen S
    J Toxicol Clin Toxicol; 1995; 33(5):463-5. PubMed ID: 7650771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis. II. Histochemical demonstration of acetylcholinesterase activity in motor end-plates of extraocular muscle in patients with myasthenia gravis; a post-mortem study.
    COHEN RB; ZACKS SI
    Am J Pathol; 1959; 35(2):399-405. PubMed ID: 13627134
    [No Abstract]   [Full Text] [Related]  

  • 4. Lens opacities in glaucoma patients on phospholine iodide therapy.
    De Roetth A
    Trans Ophthalmol Soc U K (1962); 1966; 86():89-100. PubMed ID: 5226620
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of distigmine bromide in myasthenia grauis].
    Ishikawa T; Sato Y
    Nippon Ganka Gakkai Zasshi; 1967 Dec; 71(12):2226-35. PubMed ID: 5627676
    [No Abstract]   [Full Text] [Related]  

  • 6. Cholinesterase in red cells.
    Kinyon GE
    N Engl J Med; 1969 Mar; 280(13):729-30. PubMed ID: 5766090
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of ocular symptoms in myasthenia gravis.
    Bhanushali MJ; Wuu J; Benatar M
    Neurology; 2008 Oct; 71(17):1335-41. PubMed ID: 18936425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.
    Fasano A; Bentivoglio AR; Ialongo T; Soleti F; Evoli A
    Neurology; 2005 Jun; 64(12):2155-6. PubMed ID: 15985599
    [No Abstract]   [Full Text] [Related]  

  • 9. Lcal administration of 1 per cent Ubretid in the handling of glaucoma, myasthenia gravis and esotropia.
    Ishikawa S; Tsukahara S; Sato Y
    Ophthalmologica; 1969; 159(4):339-62. PubMed ID: 5393688
    [No Abstract]   [Full Text] [Related]  

  • 10. Local administration of anticholinesterase agents in ocular myasthenia gravis.
    LEOPOLD IH; HEDGES TR; MONTANA J; KRISHNA N; BECKETT S
    Arch Ophthalmol; 1960 Mar; 63():544-7. PubMed ID: 14415845
    [No Abstract]   [Full Text] [Related]  

  • 11. Distribution of the myasthenic reaction in various muscles of patients with myasthenia gravis.
    Ozdemir C; Schwab RS; Young RR
    Trans Am Neurol Assoc; 1970; 95():300-2. PubMed ID: 5514396
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of cholinesterase inhibitors of SFEMG in myasthenia gravis.
    Massey JM; Sanders DB; Howard JF
    Muscle Nerve; 1989 Feb; 12(2):154-5. PubMed ID: 2540433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase in red cells.
    Gibbs JW
    N Engl J Med; 1969 Mar; 280(13):729. PubMed ID: 5766089
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholinesterases and contractility of cat irides. Effect of echothiophate iodide.
    Harris LS; Shimmyo M; Mittag TW
    Arch Ophthalmol; 1973 Jan; 89(1):49-51. PubMed ID: 4684897
    [No Abstract]   [Full Text] [Related]  

  • 15. [Activities of true and pseudo cholinesterases in the patients with a partial accommodative esotropia under phospholine iodide and Ubretid treatment (author's transl)].
    Kusayama M; Terakado R; Mukuno K; Ishikawa S
    Nippon Ganka Gakkai Zasshi; 1974 Feb; 78(2):93-9. PubMed ID: 4858850
    [No Abstract]   [Full Text] [Related]  

  • 16. [Myasthenia gravis with special reference to the function of intraocular muscles].
    Sato Y
    Nippon Ganka Gakkai Zasshi; 1969 May; 73(5):666-76. PubMed ID: 5389091
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic agents for alleviation of muscle weakness in myasthenia gravis (cholinesterase inhibitors)].
    Streller I
    Arzneimittelforschung; 1981; Suppl 27():73-5. PubMed ID: 7197942
    [No Abstract]   [Full Text] [Related]  

  • 18. Seronegative myasthenia gravis with bladder dysfunction.
    Marouani I; Kraoua I; Benrhouma H; Rebai I; Rouissi A; Koubaa S; Turki I; Dziri C; Gouider-Khouja N
    Rev Neurol (Paris); 2012 Mar; 168(3):299-300. PubMed ID: 22365108
    [No Abstract]   [Full Text] [Related]  

  • 19. Pseudo plus-minus lid syndrome.
    Bandini F
    Arch Neurol; 2009 May; 66(5):668-9. PubMed ID: 19433671
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of polymethylene-bis-(N-methyl-carbamic acid-m-trimethylammonium-phenol) BC 40, BC 47, BC 48 on cholinesterase activity and muscle activity in myasthenia gravis pseudoparalytica].
    PATEISKY K; HERZFELD E; STUMPF C
    Wien Klin Wochenschr; 1957 Jan; 69(1):2-7. PubMed ID: 13409866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.